Clinical trial · Observational
Clinical Outcomes of Preservation Versus Resection of Portal/Superior Mesenteric Vein During Pancreaticoduodenectomy in Pancreatic Cancer Patients Who Respond to Neoadjuvant Treatment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. There is a lack of evidence on the need to perform portal/superior mesenteric vein (PV/SMV) resection routinely in pancreatic ductal adenocarcinoma (PDAC) patients with venous involvement who responded to neoadjuvant treatment (NAT). 2. There is no significant differences in R0 rate, 5-year overall survival and recurrence-free survival between the PV/SMV preservation (PVP) group and PV/SMV resection (PVR) group. 3. PVP group showed significantly better 5-year PV/SMV stenosis free survival than the PVR group. 4. We propose that if dissection is possible and there is a high likelihood of achieving R0 resection after NAT, routine PVR may be unnecessary in PDAC patients with venous involvement.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Head Cancer Patients Who Underwent Surgery After Neoadjuvant Treatment | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| portal/superior vein resection | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Preservation of portal/superior mesenteric vein
- interventionNames
- Procedure: portal/superior vein resection
- label
- Resection of portal/superior mesenteric vein
- interventionNames
- Procedure: portal/superior vein resection
Primary outcomes (2)
- measure
- 5-year overall survival
- timeFrame
- assessed up to 60months
- description
- from diagnosis to any cause of death
- measure
- 5-year portal/superior mesenteric vein stenosis free survival
- timeFrame
- assessed up to 60months
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 79 Years
Show eligibility criteria text
Inclusion Criteria: * Pancreatic head cancer patients who underwent surgery after neoadjuvant treatment between January 2012 and December 2022 at Seoul National University Hospital Exclusion Criteria: * Metastatic unresectable and locally advanced pancreatic cancer * Resectable pancreatic cancer without portal/superior mesenteric vein invasion * Cancer aggravation after neoadjuvant treatment * Portal/superior mesenteric vein encasing and narrowing after neoadjuvant treatment * Patients who underwent palliative surgery * Non-pancreatic ductal adenocarcinoma patients * Patients who death within 30 days of surgery * Loss of follow-up patients * Patients who underwent resection for suspected main artery and adjacent organ invasion
References
Publications (0)
Data not yet available